Great product: I don't think there are many people out there who have used Rosetta Stone and would dispute that it is easy and effective. And with the addition of Totale, which allows monthly subscribers to spend an hour talking and learning with a native speaker, it works with all types of learning styles.
International growth: International growth for people who want to learn English is one of the largest growth opportunities available to this company, but international expansion has a learning curve for any company. Rosetta Stone has spent a few years working on this and has hit a few bumps along the way. Management now feels that the company is in a position to better understand how the product should work in these new markets.
Institutional growth: Another great growth opportunity lies within institutions, like international corporations, the government, K-12 schools, and even higher education organizations like Corinthian Colleges, American Public Education, and Apollo Group.
As Rosetta Stone finally makes the move to the cloud (welcome to 2011, guys!), these companies and their online-based classrooms seem like the perfect match, where both sides would absolutely benefit. And again, with such a fantastic product, building relationships and developing contracts with these institutions could provide a great source of recurring (and higher-margin) revenue for Rosetta Stone.
The numbers: This is a big one, and the main reason most investors don't want to touch this company with a 10-foot pole. Unfortunately, a great product hasn't been enough for Rosetta Stone. The company consistently misses opportunities to capitalize, which has driven the stock price down more than 60% in just three years. And things are even more painful when you compare that performance to the S&P 500:
Additionally, when recent fourth-quarter earnings were released, investors found out that while year-over-year revenues increased 5% in Q4, the company still ultimately realized a bottom-line loss in what is supposed to be its best quarter of the year. This was ahead of Wall Street's estimates, but what parent is ever happy with a D instead of an F?
New CEO: This is the big story for Rosetta Stone right now. The company recently announced that former executive Steve Swad would be the company's newest CEO. In the most recent conference call, he acknowledged that his work was cut out for him, but refrained from offering any guidance just yet for the upcoming year.
He did state, though, that he hopes to triple the size of the company. This may seem overly ambitious, but with a measly $200 million market cap and so much growth potential, the right guy could make that happen. It will be interesting to see if Swad will be the miracle worker this company has been waiting for.
Right now, Rosetta Stone is a very interesting hold for me. I love the product, and I'm intrigued by the growth opportunities and Swad's ambition. I'll be waiting for his 2012 guidance before I make any investing decisions, but I'll admit that I'm looking at a half-full glass here.
If this company is anything, it's definitely a Rule Breaker, trying to change how people around the world learn a new language. Some of our top analysts have found another rule-breaking company that they think will not only change how the medical world does things, but also provide massive profits for its investors. If you want to find out more about this company, click here to read our latest report and discover the next rule-breaking multibagger.
Fool contributor Amanda Buchanan holds no position in any company mentioned above. Click here to see her holdings and a short bio. The Motley Fool owns shares of Google, American Public Education, and Rosetta Stone. Motley Fool newsletter services have recommended buying shares of American Public Education, Rosetta Stone, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.